Healthcare Technologies (Petach Tikva, Israel) reported receiving a notice from the Nasdaq Capital Market indicating that it has regained compliance with Nasdaq's "bid price" rule, because the closing bid price per share for its ordinary shares has been above $1 per share for more than 10 consecutive trading days. As a result, the company has decided not to proceed with the previously announced proposal to effect a reverse stock split of the company's ordinary shares.

Healthcare Technologies, through it subsidiaries and affiliate, Gamidor Diagnostics, Danyel Biotech, and Savyon Diagnostics, specializes clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.